Ironwood reports FY 2022 GAAP net income $175M; FDA grants priority review for LINZESS pediatric sNDA

IRONWOOD PHARMACEUTICALS INC

2022-FY EPS reported $0.96 revenue$410,596,000

FY 2022 total revenues $410.6M (down ~1% YoY); GAAP net income $175.1M vs $528.4M in FY 2021.
Q4 2022 total revenues $107.2M; GAAP net income $48.9M ($0.27 diluted EPS).
Adjusted EBITDA for FY 2022 was $252M, up from $234M in FY 2021; cash and equivalents $656M.
FDA granted priority review for LINZESS sNDA for pediatric functional constipation (ages 6-17); PDUFA date Q2 2023.
CEO cited robust prescription demand but lower LINZESS sales growth due to retail channel inventory fluctuations.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

IRONWOOD PHARMACEUTICALS INC reported financial results for quarter and year ended December 31, 2022.

Period: quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On February 16, 2023, Ironwood Pharmaceuticals, Inc. issued a press release containing an update on its recent business activities as well as those for the quarter and year ended December 31, 2022.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

IRONWOOD PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-23-022597

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.